Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
NCT04529564
·
clinicaltrials.gov ↗
COMPLETED
Status
106
Enrollment
INDUSTRY
Sponsor class
Conditions
Carcinoma, Non-Small-Cell Lung
Sponsor
AstraZeneca